You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯港股聚焦(9.02)︱碧桂園、萬科8月銷售額同比增逾三成
格隆匯 09-02 23:05

【財務數據

數碼通電訊(00315.HK)19/20財年純利跌40.06%至3.79億港元 末期息15港仙

【運營數據】

碧桂園(02007.HK):8月權益合同銷售額609.3億元 同比增加30.10%

 萬科企業(02202.HK)8月單月銷售587.2億元 同比增長33.06%

美的置業(03990.HK)前8個月銷售額718.2億元 同比增長18.3%

中國奧園(03883.HK)8月物業合同銷售額同比增長41%至108.5億元

金地商置(00535.HK)8月銷售額達64.14億元 同比增長28.3%

合景泰富集團(01813.HK)8月預售額同比增加55.8%至96.12億元

景瑞控股(01862.HK)8月實現簽約銷售額35.17億元 同比增長76.3%

協合新能源(00182.HK)8月權益發電量增長10.32%至311.45GWh

【增減持】

睿見教育(06068.HK)控股股東劉學斌增持190萬股

【股本重組】

中國上城(02330.HK)建議“10合1”並股 擬配發7.2億股籌資7140萬港元

併購出售】

美圖公司(01357.HK)擬3.59億元收購廈門美峯科創公園物業

勵晶太平洋(00575.HK)擬379萬美元收購DLI全部股權進軍保健養生領域

天倫燃氣(01600.HK)擬1.08億元收購子洲縣順祥天然氣100%股權

【增發供股】

雅高控股(03313.HK)擬配售最多2.22億股籌資2150萬港元

滿地科技股份(01400.HK)擬折讓12.3%配股 最多籌865萬港元

泰格醫藥(03347.HK)悉數行使超額配股權發行1605.97萬股H股

【重大事項】

中國生物製藥(01177.HK):治療纖維化創新藥“TDI01”臨試申請獲CDE受理

百宏實業(02299.HK):百宏高新擬投資3.2億美元拓展聚酯薄膜業務

東陽光藥(01558.HK)H股全流通計劃完成

國藥科技股份(08156.HK)擬在香港以天祥公證行名義設立及營運口罩檢測實驗室

虎都(02399.HK)與HAFG訂立合作意向書

洛陽鉬業(03993.HK)擬以5000萬美元參與認購投資基金份額

錦江資本(02006.HK):錦江酒店擬定增募資不超50億元

白雲山(00874.HK):收到藥品再註冊批准通知書

向中國際(01871.HK)擬出資500萬元成立合營投資河南熱電產業

【回購註銷】

復星國際(00656.HK)9月2日耗資2586萬港元回購300萬股

石四藥集團(02005.HK)9月2日耗資672.6萬港元回購134.2萬股

合生創展集團(00754.HK)9月2日耗資1998萬港元回購129萬股

中國旺旺(00151.HK)9月2日耗資2342.05萬港元回購434.9萬股

金鷹商貿集團(03308.HK)9月2日耗資272萬港元回購38.1萬股

富智康集團(02038.HK)9月2日耗資133.85萬港元回購146.1萬股

DYNAM JAPAN(06889.HK)9月2日耗資319.07萬港元回購40.46萬股

百奧家庭互動(02100.HK)9月2日耗資242.52萬港元回購220萬股

中國水務(00855.HK)9月2日耗資152萬港元回購24.4萬股

康臣藥業(01681.HK)9月2日耗資162.83萬港元回購50萬股

【股權激勵】

百濟神州(06160.HK)授出可認購1080股美國存托股份的購股權

中國生物科技服務(08037.HK)授出966萬份購股權

羚邦集團(02230.HK)9月2日授出110.5萬股獎勵股份

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account